Ayesha B. Alvero, M.D., M.Sc. is a Professor in the Department of Obstetrics and Gynecology. She received her M.D. from the University of the East, Manila, Philippines and her M.Sc. in Cellular and Molecular Biology from the University of New Haven. Her first post- doctoral fellowship was in the laboratory of Dr. Barry Kacinski in the Department of Therapeutic Radiology at Yale University School of Medicine. While in Dr. Kacinski’s lab, Dr. Alvero developed a quantitative assay to measure circulating tumor cells for the prediction of chemoresponse in breast cancer patients. She then joined Dr. Gil Mor’s laboratory at the Department of Obstetrics, Gynecology, and Reproductive Sciences at Yale University School of Medicine for a second post-doctoral fellowship and focused her work in ovarian cancer.
Dr. Alvero’s research focus has been in the elucidation of mechanisms that support recurrent ovarian cancer such as those that promote inherent and acquired chemoresistance as well as mechanisms that inhibit effective anti-tumor immune responses. She led the group in the identification of key apoptotic regulators in epithelial ovarian cancer and generated robust proof-of-concept studies leading to clinical trials for Phenoxodiol, NV-128/ME-344, and Cantrixil. Dr. Alvero also led the team in the identification and characterization of the ovarian cancer stem cells and determination of their role in tumor progression. She is also instrumental in the development of unique in vitro and in vivo models that can facilitate the discovery and testing of novel diagnostic and therapeutic modalities for the management of recurrent ovarian cancer.
Alvero AB, Kim D, Lima E, Sumi NJ, Lee JS, Cardenas C, Pitruzzello M, Silasi DA, Buza N, Fahmy T, Mor G. Novel approach for the detection of intraperitoneal micrometastasis using an ovarian cancer mouse model. Sci Rep 2017; 7:40989.
Cardenas C, Montagna MK, Pitruzzello M, Lima E, Mor G, Alvero AB. Adipocyte microenvironment promotes Bclxl expression and confers chemoresistance in ovarian cancer cells. Apoptosis 2017; 22(4):558-569.
Mor G, Aldo P, Alvero AB. The unique immunological and microbial aspects of pregnancy. Nat Rev Immunol 2017; 17(8):469-482.
Cardenas C, Alvero AB, Yun BS, Mor G. Redefining the origin and evolution of ovarian cancer: a hormonal connection. Endocr Relat Cancer 2016; 23(9):R411-22.
Alvero AB, Heaton A, Lima E, Pitruzzello M, Sumi N, Yang-Hartwich Y, Cardenas C, Steinmacher S, Silasi DA, Brown D, Mor G. TRX-E-002-1 Induces c-Jun-Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo. Mol Cancer Ther 2016; 15(6):1279-90.
Yang-Hartwich Y, Soteras MG, Lin ZP, Holmberg J, Sumi N, Craveiro V, Liang M, *Romanoff E, Bingham J, Garofalo F, Alvero A, Mor G. p53 protein aggregation promotes platinum resistance in ovarian cancer. Oncogene 2015; 34(27):3605-16.
Yang-Hartwich Y, Gurrea-Soteras M, Sumi N, Joo WD, Holmberg JC, Craveiro V, Alvero AB, Mor G. Ovulation and extra-ovarian origin of ovarian cancer. Sci Rep 2014; 4:6116.
Alvero AB, Montagna MK, Sumi NJ, Joo WD, Graham E, Mor G. Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: implication for maintenance therapy with glycolysis inhibitors. Oncotarget 2014;5 (18):8703-15.